Both domestic and international guidelines recommend neoadjuvant therapy combined with localized surgical excision as the first-line targeted therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive BC patients (1, 3). Here, ERBB2 is linked to breast cancer.